This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Abaloparatide in the treatment of osteoporosis after menopause

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Abaloparatide is a synthetic peptide analogue of parathyroid hormone-related protein (PTHrP), is used to manage and treat osteoporosis (1):

  • can be combined or administered before antiresorptive therapies such as bisphosphonates to maximize effects
  • is not recommended in pediatric patients with open epiphyses or genetic predispositions to bone malignancies

NICE states (2):

  • abaloparatide is recommended as an option for treating osteoporosis after menopause in women, trans men and non-binary people, only if they have a very high risk of fracture
  • the NICE committee noted "...Clinical trial evidence shows that abaloparatide followed by alendronic acid is more effective at reducing the risk of some types of fracture than placebo followed by alendronic acid. Indirect comparisons suggest that abaloparatide is likely to work at least as well as romosozumab and teriparatide..."

Reference:

  1. Akel M, Patel P, Parmar M. Abaloparatide. [Updated 2024 Jan 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-.
  2. NICE (August 2024). Abaloparatide for treating osteoporosis after menopause

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.